The non-staff members of the IAS–USA Board of Directors participate in a volunteer capacity. They are not compensated for their role in governing/overseeing the IAS–USA.

In accordance with IAS–USA policy on disclosure and conflicts of interest, information regarding conflicts of interest is obtained from all parties with control over activity content (ie, directors, officers, activity chairs, faculty, authors, and IAS–USA staff), and conflicts of interest of those parties are resolved.

Below are the financial interests that the volunteer members of the Board of Directors have had with commercial companies within the last 12 months of the date of disclosure (noted next to each):

Dr Benson has received research grants awarded to the University of California San Diego from Gilead Sciences, Inc. She has served on advisory boards for GlaxoSmithKline and Merck & Co, Inc, and has chaired data and safety monitoring boards for Johnson & Johnson Research Pty, Ltd (Australia) and Achillion Pharmaceuticals, Inc. (Updated 12/01/09)

Dr Currier has received research grants awarded to the University of California, Los Angeles from Merck & Co, Inc, Schering-Plough Corp, Theratechnologies Inc, and Tibotec Therapeutics. She has served as a scientific advisor to Bristol-Myers Squibb, Merck & Co, Inc, and has served on data and safety monitoring boards for Achillion Pharmaceuticals, Inc, and Koronis Pharmaceuticals. (Updated 10/09/09)

Dr del Rio has received research grants awarded to Emory University from the National Institutes of Health, the US Centers for Disease Control and Prevention, Merck & Co, Inc, and Sanofi Pasteur. He served as a consultant to, or received honoraria from, Bristol-Myers Squibb, Merck & Co, Inc, and Janssen-Cilag. (Updated 10/02/09)

Dr Gallant has served as a paid lecturer for Monogram Biosciences, Inc, and has been a consultant to Abbott Laboratories and Japan Tobacco. He has been a member of data and safety monitoring boards for Gilead Sciences, Inc, and Sangamo Biosciences, Inc and has been a member of scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck Serono, RAPID Pharmaceuticals AG, and Tibotec Therapeutics. Johns Hopkins University has been the recipient of research grants or contracts from Roche Laboratories for research conducted by Dr Gallant. (Updated 11/30/09)

Dr Gulick has served as a consultant to Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Virostatics. (Updated 11/25/09)

Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 09/01/09)

Dr Richman has been a consultant to Anadys Pharmaceuticals, Inc, Biota, Bristol-Myers Squibb, Chimerx, Gen-Probe, Inc, Gilead Sciences, Inc, Hoffman-La Roche, Inc, Idenix Pharmaceuticals, Inc, Merck & Co, Inc, Monogram Biosciences, Inc, Myriad Genetics, Inc, Pfizer Inc, and Theraclone Sciences. He has been on an endpoint adjudication committee for Schering-Plough Corp and has been the recipient of research grants or contracts from Merck & Co, Inc. Dr Richman has been a stock options holder of Chimerx and Idenix Pharmaceuticals, Inc, and a stock shareholder of Monogram Biosciences, Inc. (Updated: 10/09/09)

Dr Saag has received grants and research support from and has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Roche Laboratories, Tibotec Therapeutics, and Virco Lab, Inc. (Updated 02/01/10)

Dr Schooley has served as a consultant to Achillion Pharmaceuticals, Inc, Anadys Pharmaceuticals, Inc, Ardea Biosciences, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, iTherX, Inc, LabCorp, Merck & Co, Inc, Pfizer Inc, TaiMed Biologics, and Vertex Pharmaceuticals, Inc. He has stock options for Achillion Pharmaceuticals, Inc and iTherX, Inc. (Updated 10/6/09)

Dr Volberding has been a member of the data and safety monitoring boards Merck & Co, Inc and TaiMed Biologics and on an endpoint adjudication committee for Schering-Plough Corp. He has provided paid legal consultation and expert testimony for commercial firms. Dr Volberding has served on scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Pfizer Inc, and Tobira Therapeutics and he has been the recipient of service grants for, or held contracts from, GlaxoSmithKline Italy. (Updated 10/09/09)